AMR INDUSTRY ALLIANCE Fourth PROGRESS REPORT
AMR Industry Alliance Progress Report
2023 Member Survey
The AMR Industry Alliance’s Progress Report reflects on collective achievements from the life sciences industry to minimize the spread of antimicrobial resistance (AMR). Findings from the leading coalition of biotechnology, diagnostics, generic and large research-based pharmaceutical companies indicate continued focus and leadership from the life sciences sector. Industry is helping to shape a positive future outlook in the fight against AMR but continued cross-sector collaborations along with policy and regulatory changes toward a more sustainable marketplace are needed. The report’s findings represent collective results from across Alliance membership on their current AMR activities related to research and science, access, appropriate use, and manufacturing and the environment. The report was conducted by RAND Europe.
Key findings include:
- Alliance Members are making efforts to comply with manufacturing standards. Members with their own manufacturing facilities were in compliance with CAMF criteria over 90% of the time and suppliers for members were in compliance over 50% of the time.
The report is based on independent, quality assured research conducted by RAND Europe and funded by the AMR Industry Alliance.
AMR INDUSTRY ALLIANCE MEMBERS
The AMR Industry Alliance was established in 2017. Representing a diverse coalition of biotechnology, diagnostics, generics, and large research-based biopharmaceutical companies and associations, the Alliance drives progress on AMR by the life sciences industry. With approximately 100 companies and trade associations from 20 countries, it covers nearly one third of the global antibiotic supply and the majority of novel products.
For the full list of members, please follow this link.